Artificial intelligence-focused company expands kidney care platform with anemia care tool
Click Here to Manage Email Alerts
Dosis, described in a press release as “a market leader in artificial intelligence-powered precision dosing,” has developed a new tool to personalize anemia management in chronic kidney disease.
The release noted that the tool, known as strategic iron advisor (SIA), is the first precision dosing tool on the market for IV iron; it was designed to work with the company’s strategic anemia advisor (SAA) which, according to the release, is already utilized nationwide for the personalization of erythropoiesis stimulating agent (ESA) dosing.
“This release [of SIA] is a major step toward realizing Dosis’s goal of becoming the standard of care for chronic disease management,” Shivrat Chhabra, co-founder and CEO of Dosis, said in the press release. “SIA demonstrates the extensibility of the Dosis platform.”
The release highlighted the ways in which utilizing SIA with SAA can aid clinicians in managing anemia in their patients, suggesting that because there are often separate protocols for ESAs and IV iron, using the tools together will allow for simultaneous dosing recommendations which can “ease operational burden.”
“By optimizing anemia management, clinics can reduce the utilization of both ESAs and IV iron, which reduces patient exposure to the drugs and the clinical cost of care,” according to the release. “Clinics that use SAA are able to reduce their drug utilization by 25% on average, while maintaining or improving quality outcomes. Results with SIA are expected to be similar in magnitude.”
Divya Chhabra, co-founder and chief operating officer of Dosis, also commented on the addition of SIA to the company’s kidney care platform.
“The release of SIA allows us to deepen our collaboration with our partner clinics and offer them a truly comprehensive solution for anemia management,” she said.
Click Here to Manage Email Alerts